Combination Comprising a Cyclin Dependent Kinase 4 or Cyclin Dependent Kinase (CDK4/6) Inhibitor for Treating Cancer

Patent metadata

Field	Value
Publication number	US-2016008367-A1
Application number	US-201514800893-A
Country	US
Kind code	A1
Filing date	Jul 16, 2015
Priority date	Apr 13, 2010
Publication date	Jan 14, 2016
Grant date	—

Abstract

A combination of a CDK4/6 inhibitor and an mTOR inhibitor for the treatment of cancer.

First claim

1 - 52 . (canceled)

53 . A combination comprising a first agent that is a cyclin dependent kinase 4 or cyclin dependent kinase 6 (CDK4/6) inhibitor and a second agent that is an mTOR inhibitor, wherein the first agent is 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide or a pharmaceutically acceptable salt thereof.

54 . The combination of claim 53 , wherein the second agent is selected from the group consisting of rapamycin (AY-22989), everolimus, CCI-779, AP-23573, MK-8669, AZD-8055, Ku-0063794, OSI-027, WYE-125132.

55 . The combination of claim 54 , wherein the second agent is everolimus.

56 . The combination of claim 53 , wherein the first agent and the second agent are in a combined dosage form.

57 . The combination of claim 53 wherein the first agent and the second agent are in separate dosage forms.

58 . A method of treating cancer comprising administering a first agent that is a cyclin dependent kinase 4 or cyclin dependent kinase 6 (CDK4/6) inhibitor and a second agent that is an mTOR inhibitor wherein the first agent is 7-Cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide or a pharmaceutically acceptable salt thereof.

59 . The method of claim 58 wherein the cancer is dependent on the CDK4, CDK6 or mTOR pathway.

60 . The method of claim 59 wherein the cancer is a solid tumor cancer.

61 . The method of claim 58 , wherein the cancer is pancreatic cancer, breast cancer, mantle cell lyomphoma, non-small cell lung cancer, melanoma, colon cancer, esophageal cancer, liposarcoma, multiple myeloma, T-cell leukemia, renal cell carcinoma, gastric cancer, renal cell carcinoma, glioblastoma, hepatocellular carcinoma, gastric cancer, lung cancer or colon cancer.

62 . The method of claim 61 , wherein the cancer is pancreatic cancer, breast cancer, or mantle cell lyomphoma.

63 . The method of claim 58 , wherein the cancer is a lymphoma.

64 . The method of claim 58 wherein the first agent and the second agent are administered in a combined dosage form.

65 . The method of claim 58 wherein the first agent and the second agent are administered in separate dosage forms.

66 . The method of claim 58 wherein the second agent is everolimus.

Assignees

• Borland Maria
• Brain Christopher Thomas
• Doshi Shivang
• Kim Sunkyu
• Ma Jianguo
• Murtie Josh
• Zhang Hong
• Novartis Ag

Inventors

• Borland Maria
• Brain Christopher Thomas
• Doshi Shivang
• Kim Sunkyu
• Ma Jianguo
• Murtie Josh
• Zhang Hong

Classifications

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K31/436

  the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin · CPC title

• A61K31/519 Primary

  ortho- or peri-condensed with heterocyclic rings · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61K31/5025

  ortho- or peri-condensed with heterocyclic ring systems · CPC title